Class Action Reminder for Aldeyra Therapeutics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: Globenewswire
- Class Action Initiated: Robbins LLP reminds all investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, that a class action has been filed, alleging the company misled investors regarding clinical trial results, potentially leading to significant investor losses.
- Inconsistent Clinical Trial Results: The lawsuit claims that Aldeyra failed to disclose inconsistencies in the clinical trial results for its lead drug candidate reproxalap, rendering any positive findings unreliable and affecting the credibility of the company's business and prospects, which may diminish investor confidence in the company's future.
- Stock Price Plummet: Following the receipt of a Complete Response Letter from the SEC on March 17, 2026, indicating a lack of substantial evidence for the drug's efficacy, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share, reflecting extreme market pessimism regarding the company's outlook.
- Shareholder Action Recommended: Investors are encouraged to submit their papers by May 29, 2026, to serve as lead plaintiffs in the class action, although they can still recover without participating, indicating that shareholders have opportunities to protect their rights amidst this situation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.230
Low
9.00
Averages
9.50
High
10.00
Current: 2.230
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Levicept Appoints New CFO to Drive Strategic Growth
- Executive Appointment: Levicept Ltd (ALDX) has appointed Darlene Deptula-Hicks as the new CFO, succeeding the departing Nicholas Stern, with this executive transition aimed at strengthening financial leadership to support future growth.
- Clinical Data Highlight: This appointment coincides with exceptional Phase II data for Levicept's lead candidate, LEVI-04, indicating the company's potential in the neurotrophin-3 inhibitor space, which may lay the groundwork for future market performance.
- Extensive Financial Experience: Deptula-Hicks brings decades of international financial leadership, having served as CFO at F-star Therapeutics, showcasing her deep background in both public and private life science markets, which is expected to enhance Levicept's strategic financial management.
- Multiple Board Roles: She currently holds board positions at Aldeyra Therapeutics and Lytix Biopharma, further amplifying her influence in the life sciences sector, which may support Levicept's strategic partnerships and market expansion.
See More
Levicept Appoints New Chief Financial Officer
- Executive Appointment: Levicept has appointed Darlene Deptula-Hicks as Chief Financial Officer, who brings extensive international experience in biotechnology and pharmaceuticals, having previously served as CFO at F-star Therapeutics where she successfully led an $85 million PIPE financing and Nasdaq listing.
- Clinical Trial Results: LEVI-04 has demonstrated significant pain relief and a good safety profile in a Phase II trial involving over 500 patients, highlighting its potential in treating osteoarthritis, with a market opportunity estimated to exceed $10 billion.
- Strategic Development: Darlene's appointment is expected to strengthen Levicept's senior team, supporting the company's strategic goals in the late-stage development of LEVI-04, aiming to provide a novel non-opioid therapeutic option for millions of osteoarthritis patients worldwide.
- Leadership Experience: With her extensive background in senior leadership roles across biotechnology, pharmaceuticals, and medical devices, Darlene is well-equipped to support the company through IPOs and major capital raises, potentially unlocking new growth opportunities for Levicept.
See More
Aldeyra Appoints New Board Member
- New Board Appointment: Aldeyra Therapeutics has appointed Darlene Deptula-Hicks to its board, bringing over 30 years of experience in biotechnology, which is expected to significantly enhance the company's strategic direction.
- Extensive Industry Background: Currently serving as CFO of Normunity Inc. and previously at F-star Therapeutics, Deptula-Hicks's expertise will aid Aldeyra in navigating financial and strategic challenges during potential product commercialization.
- Focus on Sustainable Growth: Deptula-Hicks expressed her eagerness to collaborate with the board and leadership team to drive Aldeyra's sustainable long-term growth, indicating a proactive approach to new product development and market expansion.
- Innovative Therapeutic Solutions: Aldeyra is dedicated to developing innovative therapies for immune-mediated diseases, with product candidates like reproxalap for dry eye disease and allergic conjunctivitis, showcasing the company's potential to address unmet medical needs.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that May 29 is the critical deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Aldeyra Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aldeyra Therapeutics on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, indicating significant legal challenges that could impact the company's stock price and market confidence.
- Allegation Details: The lawsuit alleges that the defendants issued false and misleading statements and failed to disclose material adverse facts regarding Aldeyra's business and operations, particularly the inconsistency of reproxalap clinical trial results, which may have led to investor losses.
- Investor Rights Protection: Investors must apply by May 29, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the urgency of the legal process and its potential impact on investor decisions and future legal actions.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, underscoring its expertise and influence in protecting investor rights.
See More
Levicept Appoints New CFO to Drive Strategic Growth
- Executive Appointment: Levicept Ltd (ALDX) has appointed Darlene Deptula-Hicks as the new CFO, succeeding the departing Nicholas Stern, with this executive transition aimed at strengthening financial leadership to support future growth.
- Clinical Data Highlight: This appointment coincides with exceptional Phase II data for Levicept's lead candidate, LEVI-04, indicating the company's potential in the neurotrophin-3 inhibitor space, which may lay the groundwork for future market performance.
- Extensive Financial Experience: Deptula-Hicks brings decades of international financial leadership, having served as CFO at F-star Therapeutics, showcasing her deep background in both public and private life science markets, which is expected to enhance Levicept's strategic financial management.
- Multiple Board Roles: She currently holds board positions at Aldeyra Therapeutics and Lytix Biopharma, further amplifying her influence in the life sciences sector, which may support Levicept's strategic partnerships and market expansion.
See More
Levicept Appoints New Chief Financial Officer
- Executive Appointment: Levicept has appointed Darlene Deptula-Hicks as Chief Financial Officer, who brings extensive international experience in biotechnology and pharmaceuticals, having previously served as CFO at F-star Therapeutics where she successfully led an $85 million PIPE financing and Nasdaq listing.
- Clinical Trial Results: LEVI-04 has demonstrated significant pain relief and a good safety profile in a Phase II trial involving over 500 patients, highlighting its potential in treating osteoarthritis, with a market opportunity estimated to exceed $10 billion.
- Strategic Development: Darlene's appointment is expected to strengthen Levicept's senior team, supporting the company's strategic goals in the late-stage development of LEVI-04, aiming to provide a novel non-opioid therapeutic option for millions of osteoarthritis patients worldwide.
- Leadership Experience: With her extensive background in senior leadership roles across biotechnology, pharmaceuticals, and medical devices, Darlene is well-equipped to support the company through IPOs and major capital raises, potentially unlocking new growth opportunities for Levicept.
See More
Aldeyra Appoints New Board Member
- New Board Appointment: Aldeyra Therapeutics has appointed Darlene Deptula-Hicks to its board, bringing over 30 years of experience in biotechnology, which is expected to significantly enhance the company's strategic direction.
- Extensive Industry Background: Currently serving as CFO of Normunity Inc. and previously at F-star Therapeutics, Deptula-Hicks's expertise will aid Aldeyra in navigating financial and strategic challenges during potential product commercialization.
- Focus on Sustainable Growth: Deptula-Hicks expressed her eagerness to collaborate with the board and leadership team to drive Aldeyra's sustainable long-term growth, indicating a proactive approach to new product development and market expansion.
- Innovative Therapeutic Solutions: Aldeyra is dedicated to developing innovative therapies for immune-mediated diseases, with product candidates like reproxalap for dry eye disease and allergic conjunctivitis, showcasing the company's potential to address unmet medical needs.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that May 29 is the critical deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Aldeyra Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aldeyra Therapeutics on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, indicating significant legal challenges that could impact the company's stock price and market confidence.
- Allegation Details: The lawsuit alleges that the defendants issued false and misleading statements and failed to disclose material adverse facts regarding Aldeyra's business and operations, particularly the inconsistency of reproxalap clinical trial results, which may have led to investor losses.
- Investor Rights Protection: Investors must apply by May 29, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the urgency of the legal process and its potential impact on investor decisions and future legal actions.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, underscoring its expertise and influence in protecting investor rights.
See More
